GlassScriptPhysician profile
Brandon Gregory Twombly
NPI 1013595396
$2,278.41
in general payments reported to CMS, 2019-2025
29 companies · $1,495 in 2025
The $1,495 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $63.70 · 2024: $720 · 2025: $1,495.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,278.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,278.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $346.63 | 2024-2025 | |
| Sun Pharmaceutical Industries INC. | $275.98 | 2024 | |
| Novo Nordisk INC | $236.24 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $154.33 | 2024-2025 | Airsupra, Breztri |
| Exact Sciences Corporation | $94.92 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $91.48 | 2024-2025 | Caplyta |
| Eisai INC. | $88.91 | 2024-2025 | |
| Pfizer INC. | $83.39 | 2025 | |
| Lundbeck LLC | $80.40 | 2025 | Rexulti |
| Phathom Pharmaceuticals, INC. | $73.26 | 2024-2025 | Voquezna |
| Sanofi-Aventis U.S. LLC | $70.99 | 2024-2025 | |
| Lilly USA, LLC | $63.31 | 2024-2025 | Mounjaro, Zepbound |
| Amgen INC. | $60.86 | 2025 | Evenity, Prolia |
| Glaxosmithkline, LLC. | $57.41 | 2025 | Trelegy Ellipta |
| Axsome Therapeutics, INC. | $56.36 | 2025 | Auvelity |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $55.82 | 2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $46.57 | 2023 | Jublia, Arazlo, Duobrii |
| Merck Sharp & Dohme LLC | $43.97 | 2023-2025 | Lagevrio, Vaxneuvance |
| Dexcom, INC. | $34.03 | 2025 | Dexcom G6 Transmitter |
| Irhythm Technologies, INC. | $33.65 | 2024 | Zio Xt Patch, Zio Monitor |
| Teva Pharmaceuticals USA, INC. | $33.21 | 2025 | Austedo Xr, Ajovy |
| Daiichi Sankyo INC. | $29.71 | 2025 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $27.77 | 2025 | |
| Almatica Pharma LLC | $26.57 | 2025 | Teriparatide, Loreev Xr |
| Boston Scientific Corporation | $26.42 | 2025 | Ams 700 |
| Janssen Pharmaceuticals, INC | $24.22 | 2024 | Spravato |
| Helsinn Therapeutics (U.S.), INC. | $23.29 | 2024 | Valchlor |
| E.R. Squibb & Sons, L.L.C. | $19.89 | 2025 | Eliquis |
| Vertex Pharmaceuticals Incorporated | $18.82 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Twombly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.